Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Philippe Merle, Jean Frederic Blanc, Jean Marc Phelip, Gilles Pelletier, Jean Pierre Bronowicki, Yann Touchefeu, Georges Pageaux, René Gerolami, François Habersetzer, Eric Nguyen-Khac, Andrea Casadei-Gardini, Ivan Borbath, Albert Tran, Henning Wege, Amr Shafik Saad, Massimo Colombo, Armand Abergel, Carine Richou, Imam Waked, Nelson S. YeeAudrey Molé, Pierre Attali, Julie Le Boulicaut, Bérangère Vasseur, Driffa Moussata, Jean Didier Grangé, Vlad Ratziu, Faiza Khemissa-Akouz, Hélène Regnault, Barbara Dauvois, Jean Pierre Zarski, Isabelle Ollivier-Hourmand, Sylvain Manfredi, Marilyne Debette-Gratien, Alice Gangloff, Thierry Fontanges, Aurore Baron, Mohamed Bouattour, Julie Vincent, Wolfgang Sieghart, Andreas Maieron, Marc Peeters, Jean Delwaide, Luc Lasser, Thomas Berg, Michael Schultheiß, Alexander Zipprich, Joerg Trojan, Ursula Ehmer, Gabriele Luppi, Giovanni Luca, Stefano Tamberi, Domenico Amoroso, Oscar Alabiso, Angela Buonadonna, Pierluigi Toniutto, Emiliano Tamburini, Antonio Cubillo, Andrés Muñoz, Carmen Guillén, Gloria Sánchez, Hermini Manzano, Victor Navarro, Inmaculada Ales, Bartomeu Massuti, Magdolna Dank, György Bodoky, Zsuzsanna Kahan, Zsolt Horváth, Nashat Gabrail, Howard Ozer, Christos Galanopoulos, Ralph Hauke, Moses Raj, Hakan Harputluoglu, Alper Sevinc, Erdem Goker, Ahmet Coker, Suayib Yalcin, Muhammet Ali, Ozlem Ata, Ilkay Tugba, Mohammed ElKassas, Amr Abdel, Imam Wakid, Sameh Shamaa, Nasr El, Hanaa Kohail, Jawad Makarem, Issam Chehade, Fadi Farhat, Carlos López, Miguel Marín

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Fingerprint

Medicine & Life Sciences